Genome-wide association studies identify genetic determinants of synucleinopathy biomarkers.
This genome-wide association study identifies both established and novel genetic variants that significantly modulate cerebrospinal fluid, plasma, and urine biomarkers in α-synucleinopathies, highlighting the critical need to account for genetic background when interpreting these biomarkers for diagnosis and therapeutic development.